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OBJECTIVES We sought to compare the effects of two different beta-blockers, carvedilol and metoprolol,
to an angiotensin-converting enzyme (ACE) inhibitor (captopril) on myocardial collagen
deposition during healing and ventricular remodeling after myocardial infarction (MI).
BACKGROUND Beta-adrenergic blockade has been shown to be beneficial post-MI and in chronic heart
failure. Carvedilol is a new-generation vasodilating beta-blocker with additional alpha1-
adrenoceptor antagonism and an antiproliferative action, but it is not known if it is more
beneficial than standard selective beta-blockers.
METHODS Using a rat model of MI, induced by left coronary ligation, we studied the effects of 11 weeks
of therapy with oral carvedilol, metoprolol or captopril on hemodynamics, tissue weights,
collagen volume fraction and hydroxyproline content.
RESULTS Both beta-blockers caused similar decreases in heart rate and LVEDP compared with
untreated post-MI rats. At equivalent beta-adrenoceptor blocking doses, however, carvedilol,
but not metoprolol, attenuated the increase in collagen content in noninfarcted regions and
prevented the increase in right ventricular weight/body weight (all p , 0.05), and its effect
was similar to captopril. Metoprolol treatment tended to increase right ventricular weight and
heart weight (p , 0.05). There were no differences in infarct size between the groups.
CONCLUSIONS Long-term treatment with both beta-blockers, as well as an ACE inhibitor, benefited the
healing process in rats post-MI. At equivalent myocardial beta-adrenoceptor blocking doses,
however, carvedilol significantly reduced myocardial collagen in the noninfarcted myocardium
and cardiac hypertrophy in the right ventricle, whereas metoprolol had no effect on
myocardial collagen deposition. (J Am Coll Cardiol 2000;36:276–81) © 2000 by the
American College of Cardiology
Since the early study in Sweden in 1975 (1), the possibility
that long-term therapy with beta-blockers might produce
hemodynamic and clinical benefit has been increasingly
recognized (2–4). The most commonly used beta-blocker
has been metoprolol, a traditional beta1-selective adreno-
ceptor agent (1–5). Carvedilol is a new-generation vasodi-
lating beta-adrenergic antagonist with additional alpha1-
adrenoceptor antagonist activity introduced for the
treatment of mild to moderate hypertension, and it is
currently being evaluated in clinical trials in patients with
heart failure (6,7). However, there is debate whether the
nonselective beta- and alpha-blockade and ancillary anti-
proliferative properties of carvedilol offer advantages over
traditional beta1-selective agents (8).
The amount of myocardial collagen deposition in in-
farcted and noninfarcted regions during healing after myo-
cardial infarction (MI) influences and is integral to the
process of ventricular remodeling (9). Excessive accumula-
tion of myocardial collagen may result in rigidity of the
myocardium and severely impair relaxation (10,11). In
animal studies, carvedilol has been shown to have many
additional properties, including vasodilation mediated by
alpha1-adrenoceptor antagonism, antioxidant, antiprolifera-
tive activities and reduction of infarct size in hearts with
acute MI (12–14). However, there is little information
concerning the effects of long-term beta-blockade by carve-
dilol on myocardial collagen deposition post-MI. In this
study, we have investigated the effect of long-term treat-
ment with carvedilol and metoprolol on myocardial collagen
deposition, in comparison with ACE inhibitor therapy
during healing and ventricular remodeling after coronary
ligation in rats.
METHODS
Experimental infarction. Left ventricular (LV) infarction
was induced by the method of Selye et al. (15). Male
Sprague-Dawley rats weighing 200 to 250 g were anesthe-
tized with sodium pentobarbital (30 mg/kg, i.p.), and
ventilated by positive pressure through an animal respirator
(Phipps and Bird, Inc., Richmond, Virginia). A left thora-
cotomy was performed in the fifth or sixth intercostal space,
and the left coronary artery was ligated near its origin. The
chest was closed and the rat was allowed to recover. We
experienced a 45% mortality rate within 48 h after this
procedure.
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Drug administration. Carvedilol was provided by Boehr-
inger Mannheim (Mannheim, Germany), and was dissolved
in a small volume of dimethy sulphoxide (DMSO) and
diluted with 1% acetic acid in drinking water. The final
concentration of DMSO was less than 1%. The ACE
inhibitor used in the present study was captopril. Metopro-
lol and captopril were purchased from Sigma Chemical Co.
(St. Louis, Missouri), and were dissolved in drinking water.
In pilot studies, we demonstrated that the rats with MI
treated with carvedilol at a dose of 1.2 g/liter in drinking
water containing 1% DMSO and 1% acetic acid (approxi-
mate dose of 150 mg/kg/day) for four weeks demonstrated
a 22-fold rightward shift of the isoprenaline pressure-
response curve (log EC50 26.0 6 0.1 mg/kg in carvedilol-
treated rats, n 5 4, vs. 27.4 6 0.2 in untreated rats with
MI, n 5 4 p , 0.05), and 18% reduction on baseline heart
rate (325 6 10 in carvedilol-treated rats, n 5 4 vs. 397 6 8
beats/min in untreated rats with MI, n 5 4, p , 0.05). We
also confirmed that a similar overall beta-blockade was
achieved by metoprolol at a dose of 2 g/liter in drinking
water (approximate dose of 250 mg/kg/day), producing an
identical reduction of 17% in baseline heart rate (335 6 6
beats/min in metoprolol-treated rats, n 5 4). In the present
study, therefore, the doses of drugs were 1.2 g/liter carve-
dilol, and 2 g/liter metoprolol in drinking water. The dose
of captopril was 2 g/liter in drinking water, as used by
Pfeffer et al. (11).
Treatment protocol. Seven days after coronary ligation,
the surviving rats with MI were randomized into four
groups. The first group (10 rats) received carvedilol (MI-
carv). The second group (10 rats) received metoprolol
(MI-met). The third group (10 rats) received captopril
(MI-cap). In the fourth group (18 rats), 12 rats received tap
water and 6 rats received tap water contained 1% DMSO
and 1% acetic acid (MI-V). Ten sham-operated rats re-
ceived tap water as a control group (sham-V). To avoid the
early risk induced by beta-blockers on the rats with MI, the
two beta-blockers were administrated gradually as follows: a
quarter of the full dosage within the first week, a half within
the second week, and from the third week full dosage as
described above was given. The treatment was continued for
11 weeks (12 weeks after operation) in all groups. All rats
were housed under identical conditions in a 12-h light/dark
cycle and given food and water ad libitum.
Hemodynamic studies. At 12 weeks after coronary liga-
tion, rats were anesthetized with sodium pentobarbital
(50 mg/kg, i.p.), and the mean arterial pressure (MAP) was
measured via a cannula (a saline-filled PE 50 tubing), which
was inserted into the right carotid artery and connected to a
pressure transducer (model DX-60; Nihon Kohden, Tokyo,
Japan). The heart rate measurement was triggered by the
change in systemic pressure (model AT-601G; Nihon
Kohden). After MAP and heart rate were monitored, the
cannula was briefly advanced to the left ventricle for
evaluation of the left ventricular end-diastolic pressure
(LVEDP).
Infarct size measurement. After completion of the hemo-
dynamic measurements, the hearts were arrested in diastole
with intravenous 30 mM potassium chloride. The hearts
were then removed, submersed in saline and the ventricles
were divided from apex to base into four transverse sections
(2.0 to 2.2 mm thick), identified as levels 1, 2, 3, and 4,
respectively, and the right and the left ventricle of each level
were separated. Levels 1 and 3 were fixed in 10% formalin
and embedded in paraffin for the determination of infarct
size and collagen volume fraction (CVF). Level 2 was
immediately frozen for the measurement of hydroxyproline
content.
Paraffin sections (10 mm) from levels 1 and 3 of the left
ventricle were stained with hematoxyline and eosin, and
projected into a color imaging analysis system (Q500MC;
Leica Cambridge Ltd., Cambridge, England) at a magnifi-
cation of approximately 310 and traced, and the extent of
the infarcted area (IA) was marked. A planimeter was used
to obtain the mean of scar endocardial and epicardial
circumferences of the two slices, the two were summed and
infarct size was expressed as a percentage of means left
ventricular (LV) circumference.
Determination of CVF. Paraffin sections (4 mm) of level 1
from the left and the right ventricle were stained with the
collagen-specific dye Sirius red F3BA (0.5% in saturated
aqueous picric acid) according to the method of Junqueira et
al. (16). Three sections per animal and 16 fields per section
were scanned and computerized with a Leica Q500MC
digital image analyzer at a magnification of 340. The
sections from all groups were simultaneously stained in one
batch. Collagen volume fraction was obtained from the ratio
of the connective tissue areas divided by the total tissue area
within the same microscopic field. The interstitial CVF in
the noninfarcted area (NIA) of the left ventricle, as well as
in the right ventricle, was estimated using the central part of
the myocardium, excluding the subendocardium and epicar-
dium, because the profuse collagen tissue in the subendo-
cardium and epicardial coronary vessels interfered with the
accurate quantitation of myocardial interstitial collagen
content. The CVF was expressed as the mean 6 SE of all
measurements from three sections per animal. The
collagen-positive areas from all sections were determined by
a single investigator who was unaware of the experimental
groups.
Abbreviations and Acronyms
CVF 5 collagen volume fraction
DMSO 5 dimethy sulphoxide
IA 5 infarcted area
LV 5 left ventricular
LVEDP 5 left ventricular end-diastolic pressure
MAP 5 mean arterial pressure
MI 5 myocardial infarction
NIA 5 noninfarcted area
RV 5 right ventricular
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Quantification of hydroxyproline content. The right ven-
tricle, the IA of the left ventricle and the interventricular
septum were analyzed separately. Tissue samples (25 to
50 mg) were lyophilized for 8 h to a constant weight. Tissue
dry weights were determined and the samples were flushed
with nitrogen and sealed under vacuum with 6N HCl (1
ml/10 mg dry tissue weight) before boiling for 24 h at
130°C. The samples were then filtered, vacuum dried and
dissolved in 500 mm water. After the pH was raised to 6, the
hydroxyproline content was determined according to the
method of Woessnser (17). The data are expressed as
milligrams hydroxyproline per gram dry tissue weight.
Statistical analysis. All grouped data are expressed as
mean 6 SE. Comparison between groups was performed by
one-way analysis of variance followed by Bonferroni/
Dunnett’s test. Differences were considered significant at
p , 0.05.
RESULTS
None of the animals died during the 11-week treatment
protocol. The rats with measured infarct sizes less than 20%
of LV circumference were excluded from the study (two rats
in MI-V, three rats in MI-carv, one rat in MI-met and
three rats in MI-cap). One percent DMSO and 1% acetic
acid in tap water did not influent tissue weight, hemody-
namic parameters or collagen content in rats with MI.
Tissue weight and infarct size. EFFECT OF MI. The right
ventricular (RV) weight and the ratio of RV weight/body
weight were markedly increased in the rats with MI com-
pared with the sham-operated rats (Table 1). The total
heart weight and LV weight in the rats with MI were not
different from the sham-operated rats. The mean infarct
size in the rats with MI was 40% of LV circumference.
EFFECT OF TREATMENT. Carvedilol, as well as captopril,
significantly attenuated the increase in RV weight and the
ratio of RV weight/body weight in the rats with MI,
whereas metoprolol did not. There were 7% and 10%
increases in LV weight in carvedilol- and metoprolol-
treated groups, respectively. However, these increases were
not statistically significant. There were no differences in the
ratio of LV weight/body weight between beta-blocker-
treated groups and other groups. Treatment with metopro-
lol showed a significant increase in heart weight, although
the ratio of heart weight/body weight did not reach a
significant difference.
Hemodynamic parameters. EFFECT OF MI. The rats with
MI had evidence of chronic compensated heart failure,
including a lower MAP, and a higher LVEDP compared
with the sham-operated rats (Table 2). There is no differ-
ence in heart rate between the sham-operated rats and the
rats with MI.
EFFECT OF TREATMENT. Carvedilol, metoprolol and cap-
topril prevented the increase of LVEDP observed in the
untreated rats with MI, but had no effect on MAP.
Carvedilol and metoprolol caused a similar decline in heart
rate, whereas captopril had no effect.
CVF. EFFECT OF MI. In the rats with MI, a ninefold
increase in CVF (2.7 6 0.1 in sham-V vs. 34 6 4% in
MI-V, p , 0.01) was found in the IA. A 2.0-fold and a
Table 1. Effects of Long-Term Treatment With Carvedilol, Metoprolol and Captopril on
Infarct Size and Cardiac Tissue Weights in Rats With MI
Parameters Sham-V MI-V MI-carvedilol MI-metoprolol MI-captopril
N 10 16 7 9 7
Infarct size (%) 0 40 6 6% 38 6 4% 41 6 4% 39 6 3%
BW (g) 425 6 20 436 6 14 450 6 14 441 6 14 411 6 10
HW (g) 1.62 6 0.06 1.77 6 0.13 1.84 6 0.08 2.28 6 0.12* 1.61 6 0.08
LV wt (g) 1.02 6 0.04 1.16 6 0.07 1.26 6 0.06 1.32 6 0.05 1.0 6 0.03
RV wt (g) 0.25 6 0.01* 0.47 6 0.04 0.31 6 0.02* 0.43 6 0.05 0.28 6 0.02*
HW/BW (g/kg) 3.79 6 0.16 4.05 6 0.25 4.31 6 0.24 4.40 6 0.17 3.44 6 0.21
LV/BW (g/kg) 2.40 6 0.07 2.67 6 0.17 2.73 6 0.13 2.71 6 0.08 2.41 6 0.12
RV/BW (g/kg) 0.59 6 0.02* 1.07 6 0.10 0.67 6 0.04* 0.92 6 0.08 0.67 6 0.04*
Values are mean 6 SE. *p , 0.05 versus the untreated rats with MI.
BW 5 body weight; HW 5 heart weight; LV wt 5 left ventricular weight; MI 5 myocardial infarction; N 5 number of
animals; RV wt 5 right ventricular weight; V 5 vehicle only. Rat groups are as in text.
Table 2. Effects of Long-Term Treatment With Carvedilol, Metoprolol and Captopril on
Hemodynamic Parameters in Rats with MI
Parameters Sham-V MI-V MI-carvedilol MI-metoprolol MI-captopril
N 10 16 7 9 7
MAP (mm Hg) 131 6 3* 108 6 3 105 6 10 117 6 5 92 6 8
LVEDP (mm Hg) 1.6 6 0.8* 15 6 3.9 4.0 6 0.7* 3.9 6 0.7* 3.6 6 0.8
Heart rate
(beats/min)
401 6 8 395 6 9 328 6 17* 331 6 11* 403 6 23
Values are mean 6 SE. *p , 0.05 versus the untreated rats with MI.
LVEDP 5 ventricular end-diastolic pressure; MAP 5 mean arterial pressure; N 5 indicates number of rats; V 5 vehicle
only. Rat groups are as in text.
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2.2-fold elevation in CVF were found in the NIA of the left
ventricle and the RV of the rats with MI, respectively (Fig.
1).
EFFECT OF TREATMENT. Carvedilol, metoprolol and cap-
topril had no effect on CVF of the IA (36 6 4 in MI-carv,
37 6 5 in MI-met, 32 6 5% in MI-cap, p 5 NS).
Carvedilol completely inhibited the increased CVF in the
RV and partly inhibited the increased CVF in the NIA,
whereas metoprolol had no effect on CVF in both the NIA
and the RV (Fig. 1). Captopril completely prevented the
increase in CVF in the RV and slightly reduced the
increased CVF in the NIA.
Hydroxyproline content. EFFECT OF MI. In the rats with
MI, an 11-fold increase in hydroxyproline content (2.4 6
0.4 in sham-V vs. 18 6 8 mg/g dry tissue in MI-V, p ,
0.01) was found in the IA compared with the sham-
operated rats. Two-fold increases in hydroxyproline content
were found in the interventricular septum and the RV.
EFFECT OF TREATMENT. Neither carvedilol, metoprolol
nor captopril had any effect on the hydroxyproline content
in the IA (26 6 7 in MI-carv, 33 6 9 in MI-met, 32 6 6
mg/g dry tissue in MI-cap, p 5 NS). Carvedilol signifi-
cantly reduced the hydroxyproline content in the interven-
tricular septum and the RV, whereas metoprolol had no
effect on the hydroxyproline content in both the interven-
tricular septum and the RV (Fig. 2). Captopril reduced the
hydroxyproline content in the RV, but not in the interven-
tricular septum.
DISCUSSION
The hemodynamic effects of long-term treatment with
beta-blockers in patients with chronic heart failure are a
lower heart rate, a drop in systolic blood pressure, a
reduction of LVEDP and an increase in ejection fraction
(18–20). In a canine (21) and rat (22) model of chronic
heart failure, metoprolol produced a decrease in LVEDP
and an increase in left atrial shortening. To our knowledge,
to date, there are no data on the effect of long-term
treatment with carvedilol on animal models of heart failure.
Our data indicated that in rats with chronic heart failure
after MI, hemodynamic performance was preserved during
long-term treatment with both cavedilol and metoprolol,
which are consistent with previous studies in patients with
chronic heart failure.
The major finding of the present study is that at compa-
rable beta-adrenoceptor blocking doses, there was a marked
difference between the two beta-blockers with respect to
their effect on myocardial collagen deposition. The present
study is the first report demonstrating a different effect of
carvedilol and metoprolol on myocardial collagen.
Mechanism of carvedilol’s effect on collagen. The exact
mechanisms that account for the marked discrepancy be-
tween the two beta-blockers on myocardial collagen are
Figure 1. Effects of long-term treatment with carvedilol (Carv), metopro-
lol (Met) and captopril (Cap) on collagen volume fraction in the nonin-
farcted area of the left ventricle (top) and the right ventricle (bottom)
post-MI compared with untreated rats with MI taking vehicle (V) and
sham-operated rats. Values are mean 6 SE. *p , 0.05 versus untreated rats
with MI. Rat groups are as in text. Numbers of animals in each group are
as in Table 1.
Figure 2. Effects of long-term treatment with carvedilol (Carv), metopro-
lol (Met) and captopril (Cap) on hydroxyproline contents in the interven-
tricular septum (top) and the right ventricle (bottom) post-MI compared
with untreated rats with MI taking vehicle (V) and sham-operated rats.
Values are mean 6 SE. *p , 0.05 versus untreated rats with MI. Rat
groups are as in text. Numbers of animals in each group are as in Table 1.
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likely to be complex. It is unlikely that this difference is due
to their different beta1-blocking potencies, or any regulator
factors that come into play by hemodynamic changes
induced by beta-blocker treatment, because treatment with
carvedilol decreased heart rate and LVEDP to the same
extent as treatment with metoprolol. In the myocardium,
growth-promoting mechanisms include adrenoceptors (be-
ta1, beta2, alpha1), angiotensin II receptor and endothelin 1
(ET1) receptor pathways. Bristow and coworkers’ work
indicates that there are differences in adrenoceptor subtype
distribution in failing human heart as compared with that in
nonfailing human heart (23,24). The nonfailing myocar-
dium is dominated by the beta1-adrenoceptor subtype,
whereas failing myocardium exhibits a mixture of receptor
subtypes, with beta2- and alpha1-adrenoceptor comprising
approximately 50% of the total population. It has been
suggested that synthesis of myocardial collagen type I is also
regulated by norepinephrine via an indirect effect (25). In
the heart, carvedilol in the doses used in clinical practice (50
to 100 mg/day), blocks all three adrenoceptor subtypes (24).
The dose of carvedilol used in our study (150 mg/kg/day)
was high enough to block all adrenoceptor subtypes. Thus,
the alpha1-adrenoceptor blocking activity of carvedilol may
provide additional protection beyond that produced by
beta-blockade by limiting myocardial collagen formation
post-MI. In contrast to our findings, Latini et al. (22)
reported that beta-blockade by metoprolol limited myocar-
dial collagen deposition in the same model of heart failure.
In their study, however, metoprolol treatment was started
two months after coronary ligation, and treatment contin-
ued for only one month. The conflicting results may in part
be explained by the different treatment regimens. Our data
support the hypothesis that carvedilol exerts a vasodilator
effect that could enhance its efficacy and reduce the risks of
worsening heart failure during initiation of therapy, in a
fashion similar to that seen with angiotensin-converting
enzyme inhibitors.
Effect on RV hypertrophy. Despite the reduction of
LVEDP in rats with MI after metoprolol treatment, the
increased RV weight was not reduced by metoprolol in
contrast to carvedilol and captopril. This finding suggests
that the mechanisms underlying RV myocardial hypertro-
phy in untreated rats with MI and metoprolol-treated rats
are different. When LV filling pressure is elevated after MI,
RV systolic pressure increases to maintain the pressure
gradient across the pulmonary bed. Hence, the elevation of
LVEDP produced by extensive infarction would appear to
be the cause of the RV hypertrophy (26). In the metoprolol-
treated rats, however, the increased RV weight/body weight
appeared to be independent of any pressor effects and
probably was due to the increased adrenergic stimulation
found in the failing heart (27) operating through beta2, and
alpha1-adrenoceptor pathways. In addition, the increase in
myocardial beta1-adrenoceptor density during long-term
metoprolol therapy may be relevant (28). In contrast to
metoprolol, carvedilol does not upregulate downregulated
beta1-receptors (29). A similar finding was reported in a rat
model using beta-blockade with propranolol, which also
resulted in an increased LV weight/body weight, but did not
normalize the increase in the ratio of RV weight/body
weight (30).
Effect on LV hypertrophy. In our experiment, a slight
increase in LV weight was seen in both carvedilol- (7%) and
metoprolol-treated rats (10%), compared with that in
captopril-treated and untreated rats. After MI, the LV
responds to loss of myocardial tissue and function with
hypertrophy of the remaining viable myocardium, remod-
eling and increasing ventricular volume so that stroke
volume can be maintained. The fact that in our study LV
weight remained unchanged despite loss of myocardium
from infarction and development of a thin scar in captopril-
treated and untreated rats, compared with that in sham-
operated rats, suggests that hypertrophy had occurred in the
LV. The further increases in LV weight in both carvedilol-
and metoprolol-treated rats probably were caused by the
decrease in heart rate by beta-blockade. In our study, we did
not examine ventricular volume systematically. However,
the decrease in heart rate enhances diastolic filling, which
would increase diastolic wall stress and in turn act as a
stimulus to increase end-diastolic volume (31). This increase
in volume would increase systolic wall stress, which would
provide the stimulus to increase cardiac mass, as a means to
normalize systolic wall stress (30,32). Because the heart rate
changes were similar with the two drugs, this effect is likely
to be common to both drugs. But the more complete
blockade of adrenergic stimulation by carvedilol may be
associated with a greater negative inotropic effect and hence
higher ventricular volumes and wall stress. Alternatively,
there may be less loss of myocardial cells through apoptosis
or ischemia in the carvedilol group, and this may explain the
apparent anomaly that LV weight increased while collagen
is less with carvedilol treatment.
Other actions of carvedilol. The benefits of carvedilol in
the present study may not be entirely explained by its
adrenergic blocking properties. Carvedilol also exerts anti-
oxidant effects (12) and acts to reduce the proliferation of
vascular smooth muscle in vitro (13). Such effects are
potentially of therapeutic value, because heart failure is
characterized both by increased formation of oxygen free
radicals in the failing heart and by peripheral vascular
remodeling.
In summary, we have demonstrated the beneficial effects
of long-term treatment with both carvedilol, a new nonse-
lective beta-adrenergic with additional alpha1-adrenergic
receptor antagonist activity, and metoprolol, a traditional
beta1-selective agent, post-MI in rats. However, at equiv-
alent beta1-adrenoceptor blocking doses, only carvedilol
reduced the associated increase in collagen content in the
noninfarcted myocardium, and limited the cardiac hyper-
trophy in infarcted hearts in contrast to metoprolol. These
effects appeared to be influenced by specific changes inde-
pendent of changes in hemodynamics in response to the
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long-term beta-blocker treatment, and the mechanism may
be related to the inherent difference between the two
beta-blockers, such as the alpha1-adrenoceptor antagonism
or antioxidant actions of carvedilol. Indeed, we found that
carvedilol had favorable effects on preserving heart function
after MI, in a manner similar to that seen with standard
angiotensin-converting enzyme inhibitor therapy in rats.
Our results therefore support the concept that combined
beta- and alpha-adrenoreceptor blockade may have more
favorable cardioprotective effects on infarcted hearts than
selective beta-blockade alone.
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